

Specialty Guideline Management

Eligard

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Eligard	leuprolide acetate

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication¹

Treatment of advanced prostate cancer

Compendial Uses

- Prostate cancer²
- Androgen receptor positive salivary gland tumor²⁻³

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Prostate Cancer^{1,2}

Authorization of 12 months may be granted for treatment of prostate cancer.

Salivary Gland Tumor²⁻³

Authorization of 12 months may be granted for treatment of recurrent, unresectable or metastatic salivary gland tumor as a single agent or in combination with abiraterone and prednisone when the tumor is androgen receptor positive.

Continuation of Therapy

- Authorization of 12 months may be granted for continued treatment of salivary gland tumors in members requesting reauthorization when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
- Authorization of 12 months may be granted for continued treatment of prostate cancer in members requesting reauthorization who are experiencing clinical benefit to therapy (e.g., serum testosterone less than 50 ng/dL) and who have not experienced an unacceptable toxicity.

References

1. Eligard [package insert]. Fort Collins, CO: Tolmar Pharmaceuticals, Inc.; May 2024.
2. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed February 4, 2025.
3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers. Version 2.2025. Accessed February 4, 2025. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.